Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
暂无分享,去创建一个
L. Mazzucchelli | A. Bardelli | F. Di Nicolantonio | M. Nichelatti | F. Molinari | M. Frattini | S. Veronese | A. Sartore-Bianchi | S. Siena | S. Lamba | M. Martini | P. Saletti | G. Marrapese | T. Cipani | S. De Dosso
[1] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[2] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[3] L. Pollak. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[4] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Peter Kraft,et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[7] W. Scheithauer,et al. K-ras mutations and cetuximab in colorectal cancer. , 2009, The New England journal of medicine.
[8] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Wanlong Ma,et al. K-ras mutations and cetuximab in colorectal cancer. , 2009, The New England journal of medicine.
[10] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[13] F. Siannis,et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.
[14] E. Van Cutsem,et al. Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study , 2008, Clinical Cancer Research.
[15] Pierre Laurent-Puig,et al. Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.
[16] M. Moroni,et al. EGFR FISH in colorectal cancer: what is the current reality? , 2008, The Lancet. Oncology.
[17] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[19] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[20] S. Siena,et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] P. Jänne,et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[23] M. Moroni,et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[26] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[27] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[28] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[29] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[30] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[32] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[33] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[34] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[35] K. Guan,et al. Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 , 2000, The EMBO journal.
[36] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[37] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[38] J. Hancock,et al. Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.
[39] A. Norman,et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.
[40] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[41] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.